Kathryn P. Corzo

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 636 citations

Medicine, Hematology, Pharmacotherapy +15

Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design

Paul G. Richardson, Michel Attal, Frank Campana et al. · Future Oncology · 2017 · 70 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

S824 A PHASE 3 RANDOMIZED, OPEN‐LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW‐DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW‐DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · HemaSphere · 2019 · 31 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

Paul G. Richardson, Michel Attal, S. Vincent Rajkumar et al. · Journal of Clinical Oncology · 2019 · 17 citations

Medicine, Oncology, Pharmacology +9